Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411715 | 1.00 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL1738690 | 0.85 | GRM2 (0.45) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL28060767 | 0.83 | HTR6 (0.55) | ALDH1A1GAANPC1TNFRAB9A | |
| SCHEMBL23214313 | 0.82 | PSIP1 (0.52) | ALDH1A1GAADRD2NPC1TNF | |
| SCHEMBL8233359 | 0.82 | ALDH1A1 (0.47) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL7054313 | 0.82 | ALDH1A1 (0.47) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL22013565 | 0.81 | NPC1 (0.47) | ALDH1A1GAAHSD17B10DRD2NPC1 | |
| SCHEMBL5893176 | 0.80 | NR1H2 (0.51) | LOXL2NR1H2NR1H3 | |
| SCHEMBL11207039 | 0.80 | NPC1 (0.42) | ALDH1A1NPC1TNFRAB9ANOD1 | |
| SCHEMBL14406750 | 0.80 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10DRD2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117924258-A | Pyridone compound derivative and application thereof | 复旦大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004037807-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1020434-A1 | 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0093484-A2 | Antibacterial monic acid derivatives | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | ALDH1A1 785/4885GAA 4842/4885HSD17B10 850/4885 |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | ALDH1A1 1831/4885GAA 1469/4885HSD17B10 1107/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | ALDH1A1 2468/4885GAA 3885/4885HSD17B10 3324/4885 |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | ALDH1A1 2393/4885GAA 1987/4885HSD17B10 3116/4885 |
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | ALDH1A1 2340/4885GAA 3161/4885HSD17B10 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.